UBS Maintains Buy on Veracyte, Raises Price Target to $65
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.